Elie Traer is an Oncology physician affiliated with Oregon Health & Science University. OpenAlex indexes 214 publications with 8,980 citations (h-index 35); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3181 SW Sam Jackson Park Rd
Portland, OR 972393011
Telephone
503-494-9000Registry record last updated 27 Jun 2012.
Clinical trials
- Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
Sponsor: OHSU Knight Cancer Institute
- JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia
Sponsor: OHSU Knight Cancer Institute
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
17 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Syndax Pharmaceuticals, Inc.Program year20257 payments
- Stemline Therapeutics Inc.Program year20253 payments
- Astellas Pharma US IncProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
50.3%Kinase inhibitor17.5%Jakafi100%Part D<11 patientsIsocitrate Dehydrogenase 1 Inhibitor7.1%Tibsovo100%Part D<11 patients+ 6 more classes in this area
Dermatology
14.8%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor14.8%Acyclovir100%Part D≥20 patientsAnti-infectives
12.9%Azole Antifungal5.8%Posaconazole50%Voriconazole50%Part D<11 patientsFluoroquinolone Antibacterial4.4%Levofloxacin100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2026–2026 per NIH RePORTER. The latest:
- HuMarrow: A primary cell model of AML and normal marrow to accelerate translational research
Oregon Health & Science University
FY2026$638,915R01CA310898
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed <i>NPM1</i> -Mutated or <i>KMT2A</i> -Rearranged AML
Journal of Clinical Oncology
2025 - Menin Inhibition With Revumenib for <i>KMT2A</i> -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)
Journal of Clinical Oncology
2024 - Mapping the proteogenomic landscape enables prediction of drug response in acute myeloid leukemia
Cell Reports Medicine
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Richard Maziarz, MD
Oregon Health & Science University
Wayne Clark, MD
Oregon Health & Science University
Eric Simpson, MD
Oregon Health & Science University
Helmi Lutsep, MD
Oregon Health & Science University
Carl June, MD
University of Pennsylvania
Christopher Benz, MD
Buck Institute for Research on Aging
Christina Fitzmaurice, MD
Gundersen Health System
Beth Karlan, MD
Cedars-Sinai Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”